Market Place
Sourcing Support
AEON Biopharma Reports Q3 2024 Financial Results & Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
AEON Biopharma Reports Positive FDA Biosimilar Meeting Outcome
30 Sep 2024 //
GLOBENEWSWIRE
AEON Biopharma To Attend HC Wainwright Global Investment Conference
19 Aug 2024 //
GLOBENEWSWIRE
AEON Biopharma Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
AEON Biopharma To Pursue Biosimilar Pathway For ABP-450
09 Jul 2024 //
GLOBENEWSWIRE
AEON Biopharma Announces Resource Prioritization, Cost Cuts
29 May 2024 //
GLOBENEWSWIRE
AEON Biopharma Reports First Quarter 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
AEON Biopharma Provides Update on Development Pipeline
09 May 2024 //
GLOBENEWSWIRE
AEON Biopharma Reports ABP-450 Interim Migraine Prevention Data
03 May 2024 //
GLOBENEWSWIRE
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
30 Mar 2024 //
GLOBENEWSWIRE
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 2024 //
GLOBENEWSWIRE
AEON Biopharma Announces Redemption of Public Warrants
29 Mar 2024 //
GLOBENEWSWIRE
AEON Biopharma Announces $15 M Financing Transaction
19 Mar 2024 //
GLOBENEWSWIRE
AEON Announces End-of-Phase 2 Meeting with FDA on ABP-450 migrane
19 Mar 2024 //
GLOBENEWSWIRE
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450
18 Jan 2024 //
GLOBENEWSWIRE
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450
12 Dec 2023 //
GLOBENEWSWIRE
AEON Biopharma Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450
19 Oct 2023 //
GLOBENEWSWIRE
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450
29 Aug 2023 //
GLOBENEWSWIRE
AEON Receives Notice of Allowance for a Patent Covering Use of Botulinum Toxins
24 Aug 2023 //
GLOBENEWSWIRE
Strathspey Provides Clarifying Statement Regarding Form 4 Filing with SEC
16 Aug 2023 //
GLOBENEWSWIRE
AEON Biopharma Announces Closing of Business Combination with Priveterra
24 Jul 2023 //
GLOBENEWSWIRE
Priveterra Announces Completion of Business Combination with AEON Biop
21 Jul 2023 //
BUSINESSWIRE
Priveterra Announces Intention to Transfer to NYSE Upon Completion of Business Combination
11 Jul 2023 //
BUSINESSWIRE
AEON Biopharma & Priveterra Announce Arrangement of Up to $125 M of Financing
30 Jun 2023 //
GLOBENEWSWIRE
AEON Biopharma to Host Key Opinion Leader Webinar for Migraine on February 24th
14 Feb 2023 //
GLOBENEWSWIRE
AEON Confirms Strategy for ABP-450 Unaffected by Korean Court
10 Feb 2023 //
GLOBENEWSWIRE
AEON & Priveterra Announce Capital Commitment from Investors for $20M
10 Jan 2023 //
GLOBENEWSWIRE
AEON Biopharma & Priveterra Acquisition Announce Filing of S-4 Registration
27 Dec 2022 //
BUSINESSWIRE
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450
21 Dec 2022 //
GLOBENEWSWIRE
AEON to Become Publicly Listed via Merger with Priveterra Acquisition Corp.
13 Dec 2022 //
GLOBENEWSWIRE
AEON reports positive data from Phase II cervical dystonia treatment trial
26 Sep 2022 //
CLINICALTRIALSARENA
Aeon hits phase 2 goals in rare disorder
24 Sep 2022 //
FIERCEBIOTECH
AEON Biopharma Reports Positive Topline Results from Ph2 Trial of ABP-450
23 Sep 2022 //
GLOBENEWSWIRE
AEON Biopharma Raises $30 Million from Insiders
03 Aug 2022 //
GLOBENEWSWIRE
AEON Biopharma Completes Enrollment in PII Study of ABP-450 in Cervical Dystonia
11 Apr 2022 //
GLOBENEWSWIRE
Drug developer AEON Biopharma postpones $75 million IPO
08 Oct 2021 //
RENAISSANCECAPITAL
Drug developer AEON Biopharma sets terms for $75 million IPO
04 Oct 2021 //
RENAISSANCECAPITAL
Drug developer AEON Biopharma files for a $75 million IPO
17 Sep 2021 //
RENAISSANCECAPITAL
AEON Biopharma Initiates Enrollment in Ph2 Trial of ABP-450
08 Mar 2021 //
GLOBENEWSWIRE
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450
05 Apr 2020 //
GLOBENEWSWIRE
